Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gastrointestinal lymphoma.

Philip J Bierman1

  • 1University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198, USA. pjbierma@unmc.edu

Current Treatment Options in Oncology
|August 28, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study.

British journal of haematology·2023
Same author

Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma.

Annals of hematology·2021
Same author

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2020
Same author

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2020
Same author

Radiologic Differentiation of Primary CNS Posttransplant Lymphoproliferative Disorder From Brain Metastasis.

AJR. American journal of roentgenology·2020
Same author

Self-efficacy for symptom management in the acute phase of hematopoietic stem cell transplant: A pilot study.

European journal of oncology nursing : the official journal of European Oncology Nursing Society·2019
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Treatment for gastric lymphoma is evolving. Diffuse large B-cell lymphoma may respond to chemotherapy, while Helicobacter pylori-associated lymphomas are best treated with antibiotics and potentially radiation therapy.

Area of Science:

  • Gastrointestinal Oncology
  • Hematologic Malignancies
  • Clinical Trial Design

Background:

  • Treatment recommendations for gastrointestinal lymphoma are limited by a lack of prospective trials and inconsistent classification/staging.
  • Gastric diffuse large B-cell lymphoma (DLBCL) has historically been treated with surgery, but emerging data support chemotherapy.
  • Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) is now recognized as distinct, with a key role for Helicobacter pylori.

Purpose of the Study:

  • To review current treatment strategies for gastric lymphomas.
  • To highlight recent advancements in the management of diffuse large B-cell lymphoma and MALT lymphoma of the stomach.
  • To address the challenges posed by limited prospective data and classification uniformity.

Main Methods:

Related Experiment Videos

  • Review of existing literature and clinical data on gastric lymphoma treatment.
  • Analysis of treatment outcomes for diffuse large B-cell lymphoma and MALT lymphoma.
  • Discussion of the impact of Helicobacter pylori eradication on MALT lymphoma treatment.

Main Results:

  • Combination chemotherapy regimens show promise for gastric diffuse large B-cell lymphoma, similar to nodal presentations.
  • Adjuvant radiotherapy may improve outcomes for gastric diffuse large B-cell lymphoma patients.
  • Antibiotic therapy is the primary treatment for localized gastric MALT lymphoma, with radiation reserved for refractory cases.

Conclusions:

  • Gastric diffuse large B-cell lymphoma management is shifting towards chemotherapy, potentially with adjuvant radiotherapy.
  • Helicobacter pylori eradication has transformed MALT lymphoma treatment, making it highly curable with antibiotics.
  • Further prospective trials are needed to standardize classification, staging, and optimize treatment protocols for gastrointestinal lymphomas.